Skip to main content

Table 5 Selected studies for MM therapy from 2020 ASH annual meeting

From: Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting

Abstract # Authors (reference) Study agents Phase NCT No
551 Facon et al. [49] Ixazomib/Len/Dex III 01850524
549 Kaufman et al. [51] Dara/Len/Vel/Dex II 02874742
130 Alsina et al. [57] BB21217 I 03274219
134 Costello et al. [59] P-BCMA-101 I/II 03288493
129 Mailankody et al. [62] ALLO-715 I 04093596
293 Rodriguez et al. [66] TNB-383B I 03933735
290 Chari et al. [67] JNJ-7564 I 03399799
292 Cohen et al. [68] BFCR4350A I 03275103
179 Kumar et al. [70] MEDI2228 I 03489525
724 Van De Donk et al. [72] Iberdomide with
Dara/Dex or Vel/Dex
I/II 02773030
  1. Len, lenalidomide; Dex, dexamethasone; Dara, daratumumab; Vel, velcade (bortezomib)